The combination of expertise and passion to build transformative, life-changing medicines for patients and their families positions Arcturus Therapeutics to catalyze the next generation of mRNA medicines. After completion of the preclinical proof-of-concept studies on LUNAR-CF, a medicine to treat cystic fibrosis, Arcturus Therapeutics has turned to The Chase Group for their expertise in life science executive search. Retained to secure a proven leader in Pulmonary and Rare Diseases Clinical Development, The Chase Group is utilizing their vast network and 25+ years of life science recruiting experience to identify a board-certified physician in respiratory medicine. This high-profile role will report to the Chief Development Officer and have responsibility for the design and ownership of the clinical development plan while providing strategic leadership as Arcturus builds their pulmonary franchise with multiple targets. The Chase Group looks forward to collaborating with Arcturus and providing the high caliber talent needed to continue developing their portfolio of mRNA therapeutics. For more information, please contact karen@chasegroup.com
